<DOC>
	<DOCNO>NCT00522665</DOCNO>
	<brief_summary>The addition RAD001 , mTOR inhibitor , irinotecan anti-EGFR antibody cetuximab may increase efficacy patient metastatic colorectal cancer progress prior chemotherapy . This approach biologically direct overall target cancer cell multiple level , potentially prevent chemotherapy EGFR-therapy resistance .</brief_summary>
	<brief_title>Phase I/Randomized Phase II Study Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 Colorectal Cancer</brief_title>
	<detailed_description>OUTLINE : This multi-center study . PHASE I : - UGT1A1 *28 7/7 genotype IS NOT present - Cetuximab 250 mg/m2 IV day 1 , 8 , 15 - Irinotecan 125 mg/m2 IV day 1 8 - RAD001 PO QD ( dose determine time registration ; subject remain dose level treatment discontinuation ) PHASE II : - Randomization base UGT1A1 *28 7/7 Genotype Prior Irinotecan Exposure ARM A : - Cetuximab 250 mg/m2 IV day 1 , 8 , 15 - Irinotecan 125 mg/m2 IV day 1 8 AT TIME OF PROGRESSIVE DISEASE , ARM A TREATMENT WILL CROSSOVER : - Cetuximab 250 mg/m2 IV day 1 , 8 , 15 - Irinotecan 125 mg/m2 IV day 1 8 - RAD001 PO QD ( maximum tolerate dose ) ARM B : - Cetuximab 250 mg/m2 IV day 1 , 8 , 15 - Irinotecan 125 mg/m2 IV day 1 8 - RAD001 PO QD ( maximum tolerate dose ) AT TIME OF PROGRESSIVE DISEASE , ARM B TREATMENT WILL BE DISCONTINUED ECOG performance status 0-2 Life Expectancy : Not specify Hematopoietic : - Absolute neutrophil count ( ANC ) ≥ 1,500 mm3 - Platelets ≥ 100,000 mm3 - Hemoglobin ( Hgb ) ≥ 9 g/dL - White blood cell count ( WBC ) ≥ 2,000 mm3 - INR &lt; 1.5 x upper limit normal ( ULN ) anticoagulation ( anticoagulation must in-range INR ( usually 2 3 ) stable dose warfarin ) - PTT &lt; 1.5 x ULN Hepatic : - Bilirubin ≤ 1.5 x ULN - Aspartate aminotransferase ( AST , SGOT ) ≤ 2.5 x ULN - Alanine aminotransferase ( ALT , SGPT ) ≤ 2.5 x ULN - Albumin ≥ 3.0 g/dL Renal : - Calculated creatinine clearance ≥ 60 cc/min use Cockcroft-Gault formula Cardiovascular : - No uncontrolled cardiac arrhythmia require medication , transient ischemic attack ( TIA ) , cerebrovascular accident ( CVA ) within 6 month prior register protocol therapy - No uncontrolled congestive heart failure , myocardial infarction , unstable angina within 6 month prior register protocol therapy Pulmonary : - No severely impaired lung function demonstrate pulse O2 saturation ≤ 90 % rest room air , pulmonary function test FEV1 ≤ 2L - No history prior chronic lung infection tuberculosis , atypical tuberculosis , histoplasmosis evidence chest CT x-ray within 21 day prior register protocol therapy</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Histological cytological proof colon rectal adenocarcinoma Measurable site disease accord RECIST previously irradiate Must metastatic colorectal cancer progress first line chemotherapy +/ bevacizumab Blood sample collect within 21 day prior register protocol therapy UTG1A1 genotype analysis . ( Patients UGT1A1 *28 7/7 genotype ( homozygosity TA7 allele ) exclude Phase I stage study . During Phase II stage study , subject allow participate must begin treatment dose level 1 irinotecan . ) A history malignancy ( noncolorectal ) allow , provide curatively treat demonstrate evidence recurrence cancer Prior radiation therapy allow &lt; 25 % bone marrow Age ≥ 18 year time consent Written inform consent HIPAA authorization release personal health information Females childbearing potential male must willing use effective method contraception Females childbearing potential must negative pregnancy test within 7 day register protocol therapy No one prior chemotherapy regimen metastatic colorectal cancer , least 28 day prior register protocol therapy No prior treatment cetuximab No prior treatment mTOR inhibitor No known hypersensitivity cetuximab , RAD001 ( everolimus ) , rapamycins ( sirolimus , temsirolimus ) excipients No treatment investigational agent within 28 day prior register protocol therapy No symptomatic brain metastasis No uncontrolled diabetes define fast serum glucose &gt; 1.5 x ULN No chronic treatment systemic steroid another immunosuppressive agent No serious nonhealing wound , ulcer , bone fracture , major surgical procedure , open biopsy significant traumatic injury within 28 day prior register protocol therapy No liver disease cirrhosis , chronic active hepatitis chronic persistent hepatitis No active bleed pathological condition associate high risk bleed No uncontrolled systemic disease include active infection uncontrolled hypertension No known history HIV seropositivity No impairment gastrointestinal function gastrointestinal disease may significantly alter absorption RAD001 ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) No nonmalignant medical illness uncontrolled whose control may jeopardize treatment protocol therapy No plan immunization attenuate live virus study period Females must breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>